Remix CSO to speak at Discovery on Target event

💡 If you’re working with long-reads & RNA-seq analysis tools, check out LongBench: a multi-platform reference dataset spanning bulk, single-cell, and single-nucleus transcriptomics. 📊 Benchmarking using lung cancer cell line data revealed differences in read length & accuracy between long-read protocols. These differences were more subtle for single-cell preps. #RNA #Transcriptomics #SingleCell #LongReads #LungCancer

💡 This week’s Sunday Papers feature a digest of a small number of recent interesting papers in the field of translatomics. - Linc00941 fuels ribogenesis and protein synthesis by supporting robust cMYC translation in malignant pleural mesothelioma. - Proteomic Profiling of Unannotated Microproteins in Human Placenta Reveals XRCC6P1 as a Potential Negative Regulator of Translation. - The cryptic lncRNA-encoded microprotein TPM3P9 drives oncogenic RNA splicing and tumorigenesis. 🔗 https://lnkd.in/eNrudNzP #HarnessingTranslatomics #EnablingBioinnovations #RibosomeProfiling #Science #MolecularBiology

Enhanced Single-Cell LOH Profiling via Multi-Modal Data Fusion & Bayesian Inference This paper introduces a novel, immediately deployable methodology for high-resolution Loss of Heterozygosity (LOH) profiling in single cells, addressing limitations in current techniques by integrating optical microscopy, fluorescence in situ hybridization (FISH), and short-read sequencing data through a Bayesian inference framework. Our approach achieves a 10x improvement in LOH detection accuracy over existing single-cell genomic methods, enabling more precise cancer diagnostics and therapeutic target identification. We detail the entire computational pipeline, emphasizing robust statistical validation and scalability for up to millions of cells. 1. Introduction: The Challenge of Precise LOH Detection Loss of Heterozygosity (LOH) represents a critical mechanism in tumorigenesis, often driving disease progression and treatment resistance. While LOH has been extensively studied in bulk tumor samples, its analysis in single cells remains technically challenging. Current methods, primari https://lnkd.in/gMUM2X6B

🔬 𝗨𝗻𝗹𝗼𝗰𝗸 𝘁𝗵𝗲 𝗣𝗼𝘄𝗲𝗿 𝗼𝗳 𝗙𝗹𝗼𝘄 𝗖𝘆𝘁𝗼𝗺𝗲𝘁𝗿𝘆 𝗳𝗼𝗿 𝗬𝗼𝘂𝗿 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵 Flow cytometry is a powerful technology that enables rapid and precise analysis of cell populations, helping researchers measure parameters such as cell size, granularity, surface markers, and intracellular components like DNA and RNA. Widely used in immunology, oncology, pharmacology, and molecular biology, flow cytometry has become an essential tool for advancing scientific research. To support your experiments, our partner Elabscience Bionovation Inc. offers a comprehensive range of high-quality reagents and kits, including: ✅ Fluorochrome-conjugated antibodies ✅ Apoptosis detection kits (Annexin V, Mitochondrial Detection, TUNEL) ✅ Cell proliferation and cell cycle kits (CFSE, Cell Cycle) ✅ Cell viability/toxicity assays (Calcein-AM/PI) With Elabscience® solutions, you can achieve reliable, accurate, and reproducible results in every flow cytometry experiment. Learn more now: 🔗 https://lnkd.in/eA8mVPjP #Biomol #Elabscience #FlowCytometry #CellAnalysis #ResearchSolutions #YouHaveTheVisionWeHaveTheSubstance

🚀 Advancing Personalized mRNA Vaccine Design with AI Today, my AI algorithm predicted multiple high-priority epitopes with strong CD8⁺ T-cell activation (0.84) and an estimated efficacy of 0.76 — marking a key milestone in our immunogenicity modeling pipeline. These findings move us one step closer toward building personalized mRNA cancer vaccines driven by data and innovation. Proud of the progress made under Alkhaleeli BioAI LLC — bridging computational biology and clinical translation. #AI #Bioinformatics #mRNAVaccine #Innovation #Biotech #CancerResearch

Focus on Neuroblastoma. In a paper just out in Nature Communications, the authors report: "To better understand the cellular plasticity of neuroblastoma in chemoresistance, we define the transcriptomic and epigenetic map of adrenergic and mesenchymal types of neuroblastomas using human and murine models treated with indisulam, a selective RBM39 degrader. We show that cancer cells not only undergo a bidirectional switch between adrenergic and mesenchymal states, but also acquire additional cellular states, reminiscent of the developmental pliancy of neural crest cells. Through targeting RNA splicing, indisulam induces an inflammatory tumor microenvironment and enhances the anticancer activity of natural killer cells". https://lnkd.in/eQqq7GM4 (open access) FOCUS Biomolecules offers indisulam for research applications. For more info visit https://lnkd.in/ekUtjSBu #SmallMolecules #Cancerresearch #Pharmacology #Cellbiology

🔬 What if we could unlock the hidden language of cancer through RNA sequencing? Tempus AI has achieved FDA 510(k) clearance for their Tempus xR IVD device - a next-generation RNA sequencing diagnostic tool that represents a significant step in precision oncology. This in vitro diagnostic device uses targeted high-throughput hybridization-based capture technology to detect gene rearrangements, providing clinicians with deeper insights into cancer biology at the molecular level. The device analyzes RNA isolated from formalin-fixed paraffin-embedded (FFPE) tissue samples, enabling comprehensive transcriptome analysis that can guide personalized treatment strategies. This advancement in molecular diagnostics bridges the gap between genomic data and clinical decision-making, potentially transforming how we approach cancer care. How do you see RNA-based diagnostics shaping the future of precision medicine? 📰 Source: Business Wire - https://lnkd.in/dnD8m6fw #MedTech #Innovation #Healthcare #PrecisionMedicine #RNAsequencing #CancerDiagnostics #FDAapproval ---

Identifying circulating extracellular vesicle isomiR signatures to predict therapy response in multiple myeloma: in their latest work, Cristina Gómez Martín, Esther Drees, Michiel Pegtel at Amsterdam UMC and collaborators profiled plasma extracellular vesicle–bound isomiRs (pEV-isomiRs) at single-nucleotide resolution using an in-house small RNA sequencing protocol, IsoSeek, optimized for low-input liquid biopsy samples. Multiple myeloma (MM), a plasma cell neoplasm marked by extensive inter- and intra-patient clonal heterogeneity, often shows highly variable therapeutic responses. Minimally invasive biomarkers that predict response could therefore guide personalized treatment 🔗 https://lnkd.in/ecFGQNge After extensive normalization and correction, the authors generated and validated pEV-isomiR signatures with machine learning to detect active MM, monitor therapeutic response, and predict durable outcomes. Their approach required only 1 mL of plasma, was compatible with standard MiSeq Illumina sequencing, and allowed flexibility in pre-analytical conditions, simplifying its potential use in clinical practice. An article co-authored by Monique van Eijndhoven, Nils Groenewegen, Steven W., Sandra Veldt - Verkuijlen, Jan Van Weering, Ernesto Aparicio-Puerta, Leontien Bosch, Kris Frerichs, Christie Verkleij, Marie J. Kersten, Josée Zijlstra, Daphne de Jong, Catharina G.M. Groothuis-Oudshoorn, Michael Hackenberg, Johan de Rooij and Niels Van De Donk. #extracellularvesicles #exosomes #liquidbiopsy #miRNA #Vesiculab